Ethical considerations on placebo-controlled vaccine trials in pregnant women

Ana Cecilia Amado Xavier De-Oliveira, Francisco José Roma Paumgartten


Placebo use in clinical trials, whenever a proven effective treatment exists, is one of the most debated topics in contemporary research ethics. This article addresses the ethical framework for placebo use in clinical trials assessing vaccine efficacy in pregnant women. Vaccine trial participants are healthy at the outset and some must be infected during the study to demonstrate the product’s efficacy, meaning that placebo-treated participants are under risk of serious and irreversible harm. If effective vaccines exist, such risk precludes placebo use. This interdiction should be extended to any clinical trial of vaccine efficacy in pregnant women, because a demonstration of clinical efficacy in nonpregnant individuals and comparable immunogenic responses in pregnant women are predictors of efficacy in pregnancy as well. Moreover, product effectiveness in real-world use scenarios can be ascertained by observational studies conducted after its inclusion in vaccination campaigns.


Vaccines. Placebos. Clinical study. Bioethics. Therapeutic equipoise. COVID-19. Influenza, human.

Texto completo:

PDF (English) PDF PDF (Español)

Direitos autorais 2023 Revista Bioética

CC-BY. Creative Commons Attribution 4.0 International.